Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res [Internet]. 2011;20:1727–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ [Internet]. 2020;21:1245–57.

Article  PubMed  PubMed Central  Google Scholar 

Rencz F, Gulácsi L, Drummond M, Golicki D, Prevolnik Rupel V, Simon J, et al. EQ-5D in Central and Eastern Europe: 2000–2015. Qual Life Res [Internet]. 2016;25:2693–710. https://doi.org/10.1007/s11136-016-1375-6.

Article  PubMed  Google Scholar 

Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making [Internet]. 2016;36:965–72.

Article  PubMed  Google Scholar 

Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making [Internet]. 2016;22:340–9. https://doi.org/10.1177/0272989X0202200412.

Article  Google Scholar 

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J [Internet]. 2010;35:532–9. https://erj.ersjournals.com/content/35/3/532

Herdman M, Kerr C, Pavesi M, Garside J, Lloyd A, Cubi-Molla P, et al. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. J Patient Rep Outcomes [Internet]. 2020;4.

Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics [Internet]. 2017;35:33–41. https://doi.org/10.1007/s40273-017-0546-9.

Article  PubMed  Google Scholar 

Hoogendoorn M, Oppe M, Boland MRS, Goossens LMA, Stolk EA, Rutten-van Mölken MPMH. Exploring the impact of adding a respiratory dimension to the EQ-5D-5L. Medical Decision Making [Internet]. 2019;39:393.

Article  PubMed  PubMed Central  Google Scholar 

Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health [Internet]. 2013;16:1156–62.

Article  PubMed  Google Scholar 

Rencz F, Mukuria C, Bató A, Poór AK, Finch AP. A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Qual Life Res [Internet]. 2022;31:3049–60.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. An exploratory study to test the impact on three ‘bolt-on’ items to the EQ-5D. Value Health [Internet]. 2015;18:52–60.

Article  PubMed  PubMed Central  Google Scholar 

Islam N, Leung PSC, Huntley AC, Eric GM. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14:81–9.

Article  CAS  PubMed  Google Scholar 

Alopecia areata—Level 3 cause|Institute for Health Metrics and Evaluation [Internet]. [cited 2024 Jan 9]. https://www.healthdata.org/results/gbd_summaries/2019/alopecia-areata-level-3-cause.

Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers [Internet]. 2017;3:17011.

Article  PubMed  PubMed Central  Google Scholar 

Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. Mosby Inc.; 2016. p. 806-812.e3.

Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol [Internet]. 2016;175:561–71. https://doi.org/10.1111/bjd.14497.

Article  CAS  PubMed  Google Scholar 

Macey J, Kitchen H, Aldhouse NVJ, Burge RT, Edson-Heredia E, McCollam JS, et al. Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in japan. Dermatol Ther (Heidelb) [Internet]. 2021;11:433–47. https://doi.org/10.1007/s13555-020-00477-6.

Article  Google Scholar 

Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther (Heidelb) [Internet]. 2021;11:599–613. https://doi.org/10.1007/s13555-021-00508-w.

Article  Google Scholar 

Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. Br J Dermatol. 2019;180:1377–89.

Article  CAS  PubMed  Google Scholar 

Jankovic S, Peric J, Maksimovic N, Cirkovic A, Marinkovic J, Jankovic J, et al. Quality of life in patients with alopecia areata: a hospital-based cross-sectional study. J Eur Acad Dermatol Venereol [Internet]. 2016;30:840–6. https://doi.org/10.1111/jdv.13520.

Article  CAS  PubMed  Google Scholar 

Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc [Internet]. 2020;20:S62–8. http://www.jidsponline.org/article/S1087002420300174/fulltext. Accessed 28 Oct 2021.

Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol [Internet]. 2021;85:162–75. http://www.jaad.org/article/S0190962220311440/fulltext.

Masmoudi J, Sellami R, Ouali U, Mnif L, Feki I, Amouri M, et al. Quality of life in alopecia areata: a sample of Tunisian patients. Dermatol Res Pract. 2013;2013:1.

Article  Google Scholar 

A phase 3 study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata (THRIVE-AA2)—Full Text View—ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https://clinicaltrials.gov/ct2/show/NCT04797650.

A phase 3 study to evaluate the efficacy and safety of ctp-543 in adult patients with moderate to severe alopecia areata (THRIVE-AA1) —Full Text View—ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https://clinicaltrials.gov/ct2/show/NCT04518995.

A study of baricitinib (LY3009104) in adults with severe or very severe alopecia areata—Full Text View—ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https://clinicaltrials.gov/ct2/show/NCT03899259.

A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata—Full Text View—ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https://clinicaltrials.gov/ct2/show/NCT03570749.

PF-06651600 for the treatment of alopecia areata—Full Text View—ClinicalTrials.gov [Internet]. [cited 2023 Mar 2]. https://clinicaltrials.gov/ct2/show/NCT03732807.

National Institute for Health and Care Excellence. Draft guidance consultation: Baricitinib for treating severe alopecia areata [Internet]. [cited 2023 May 5]. https://www.nice.org.uk/guidance/gid-ta10941/documents/129.

Baricitinib for treating severe alopecia areata: Public Committee slides [Internet]. [cited 2023 May 5]. https://www.nice.org.uk/guidance/gid-ta10941/documents/1.

Baricitinib not recommended by NICE for routine commissioning in the NHS | Alopecia UK [Internet]. [cited 2023 May 5]. https://www.alopecia.org.uk/news/baricitinib-not-recommended-by-nice-for-routine-commissioning-in-the-nhs.

Poór AK, Rencz F, Brodszky V, Gulácsi L, Beretzky Z, Hidvégi B, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res [Internet]. 2017;26:3409–19. https://doi.org/10.1007/s11136-017-1699-x.

Article  PubMed  Google Scholar 

Bató A, Brodszky V, Gergely LH, Gáspár K, Wikonkál N, Kinyó Á, et al. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res [Internet]. 2021;30:1477–90. https://doi.org/10.1007/s11136-020-02732-x.

Article  PubMed  PubMed Central  Google Scholar 

Koszorú K, Hajdu K, Brodszky V, Bató A, Gergely LH, Kovács A, et al. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. Eur J Health Econ [Internet]. 2023;24:139–52. https://doi.org/10.1007/s10198-022-01460-y.

Article  PubMed  Google Scholar 

Baricitinib for treating moderate to severe atopic dermatitis Technology appraisal guidance. 2021 [cited 2022 Oct 26]; http://www.nice.org.uk/guidance/ta681.

Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, et al. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb) [Internet]. 2021;12:149–66. https://doi.org/10.1007/s13555-021-00648-z.

Article  Google Scholar 

Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User’s Manual for the SF-36v2 Health Survey. Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. Development. User’s Manual for the SF-36v2® Health Survey. Lincoln (RI): QualityMetric Incorporated; 2007. Lincoln: QualityMetric Incorporated; 2007.

Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol [Internet]. 1999;40:242–6. http://www.jaad.org/article/S0190962299701957/fulltext.

Strober BE, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol [Internet]. 2009;145:1262–6.

CAS  PubMed  Google Scholar 

Hernández-Alava M, Pudney S. Mapping between EQ-5D-3L and EQ-5D-5L: a survey experiment on the validity of multi-instrument data. Health Econ [Internet]. 2022;31:923–39. https://doi.org/10.1002/hec.4487.

Article  PubMed  PubMed Central  Google Scholar 

Cohen J. Statistical power analysis for the behavioral sciences. Statistical Power Analysis for the Behavioral Sciences [Internet]. 2013 [cited 2022 Oct 26]; https://doi.org/10.4324/9780203771587

Flora DB, LaBrish C, Chalmers RP. Old and new ideas for data screening and assumption testing for exploratory and confirmatory factor analysis. Front Psychol. 2012;3:18053.

Article  Google Scholar 

Burge RT, Anderson P, Austin J, Piercy J, Manuel L, Edson-Heredia E, et al. 26158 The patient-reported burden of alopecia areata by current severity: A real-world study in the US. J Am Acad Dermatol [Internet]. 2021;85:AB86. http://www.jaad.org/article/S0190962221014729/fulltext.

Brazier J, Rowen D. NICE DSU Technical Support Document 11: alternatives to EQ-5D for Generating health state utility values. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values [Internet]. 2011.